BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19735728)

  • 1. Integrin alpha(v)beta(3), metalloproteinases, and sphingomyelinase-2 mediate urokinase mitogenic effect.
    Maupas-Schwalm F; Bedel A; Augé N; Grazide MH; Mucher E; Thiers JC; Salvayre R; Nègre-Salvayre A
    Cell Signal; 2009 Dec; 21(12):1925-34. PubMed ID: 19735728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role for furin in tumor necrosis factor alpha-induced activation of the matrix metalloproteinase/sphingolipid mitogenic pathway.
    Tellier E; Nègre-Salvayre A; Bocquet B; Itohara S; Hannun YA; Salvayre R; Augé N
    Mol Cell Biol; 2007 Apr; 27(8):2997-3007. PubMed ID: 17283058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
    He Y; Liu XD; Chen ZY; Zhu J; Xiong Y; Li K; Dong JH; Li X
    Clin Cancer Res; 2007 Jun; 13(11):3115-24. PubMed ID: 17545513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A; Xue M; Jackson C; Smith RC
    Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.
    Franco P; Vocca I; Carriero MV; Alfano D; Cito L; Longanesi-Cattani I; Grieco P; Ossowski L; Stoppelli MP
    J Cell Sci; 2006 Aug; 119(Pt 16):3424-34. PubMed ID: 16882693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells.
    Mi Z; Guo H; Wai PY; Gao C; Kuo PC
    Carcinogenesis; 2006 Jun; 27(6):1134-45. PubMed ID: 16474180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.
    Tarui T; Akakura N; Majumdar M; Andronicos N; Takagi J; Mazar AP; Bdeir K; Kuo A; Yarovoi SV; Cines DB; Takada Y
    Thromb Haemost; 2006 Mar; 95(3):524-34. PubMed ID: 16525582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
    Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
    BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and activation of proteases in co-cultures.
    Paduch R; Kandefer-Szerszeń M
    Exp Toxicol Pathol; 2011 Jan; 63(1-2):79-87. PubMed ID: 19836935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T; Behrendt N; Ploug M
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
    Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
    Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation.
    Augé N; Maupas-Schwalm F; Elbaz M; Thiers JC; Waysbort A; Itohara S; Krell HW; Salvayre R; Nègre-Salvayre A
    Circulation; 2004 Aug; 110(5):571-8. PubMed ID: 15277330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue-type plasminogen activator.
    Maupas-Schwalm F; Augé N; Robinet C; Cambus JP; Parsons SJ; Salvayre R; Nègre-Salvayre A
    FASEB J; 2004 Sep; 18(12):1398-400. PubMed ID: 15231724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK.
    Hecht M; Heider U; Kaiser M; von Metzler I; Sterz J; Sezer O
    Br J Haematol; 2007 Aug; 138(4):446-58. PubMed ID: 17593251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The kringle domain of urokinase-type plasminogen activator potentiates LPS-induced neutrophil activation through interaction with {alpha}V{beta}3 integrins.
    Kwak SH; Mitra S; Bdeir K; Strassheim D; Park JS; Kim JY; Idell S; Cines D; Abraham E
    J Leukoc Biol; 2005 Oct; 78(4):937-45. PubMed ID: 16033814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
    Knappe UJ; Hagel C; Lisboa BW; Wilczak W; Lüdecke DK; Saeger W
    Acta Neuropathol; 2003 Nov; 106(5):471-8. PubMed ID: 12904990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical involvement of ILK in TGFbeta1-stimulated invasion/migration of human ovarian cancer cells is associated with urokinase plasminogen activator system.
    Lin SW; Ke FC; Hsiao PW; Lee PP; Lee MT; Hwang JJ
    Exp Cell Res; 2007 Feb; 313(3):602-13. PubMed ID: 17187779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.